Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
STALICLA Starts Phase 3 DDI Study of STP7 to Treat Cocaine Use Disorder in the U.S.
Details : STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). It is being evaluated for the treatment of cocaine use disorder.
Brand Name : STP7
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 02, 2024
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.
Brand Name : STP7
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 08, 2023
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : National Institute on Drug Abuse
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5...
Brand Name : AFQ056
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 09, 2023
Lead Product(s) : Mavoglurant
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $270.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?